These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19082568)

  • 41. Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.
    Haerter F; Simons JC; Foerster U; Moreno Duarte I; Diaz-Gil D; Ganapati S; Eikermann-Haerter K; Ayata C; Zhang B; Blobner M; Isaacs L; Eikermann M
    Anesthesiology; 2015 Dec; 123(6):1337-49. PubMed ID: 26418697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Sugammadex--two years in clinical practice].
    Glinka L; Onichimowski D; Sieniuta P; Korecki A
    Anestezjol Intens Ter; 2010; 42(3):155-9. PubMed ID: 21413422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment.
    Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Hunter JM; Sculpher M; Woolacott N
    Br J Anaesth; 2010 Nov; 105(5):568-75. PubMed ID: 20937718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?
    Meistelman C; Donati F
    Curr Opin Anaesthesiol; 2016 Aug; 29(4):462-7. PubMed ID: 27168088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients.
    McDonagh DL; Benedict PE; Kovac AL; Drover DR; Brister NW; Morte JB; Monk TG
    Anesthesiology; 2011 Feb; 114(2):318-29. PubMed ID: 21239968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sugammadex and rocuronium-induced anaphylaxis.
    Takazawa T; Mitsuhata H; Mertes PM
    J Anesth; 2016 Apr; 30(2):290-7. PubMed ID: 26646837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Worldwide experience with sugammadex sodium: implications for the United States.
    Welliver M; Cheek D; Osterbrink J; McDonough J
    AANA J; 2015 Apr; 83(2):107-15. PubMed ID: 26016169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Jones RK; Caldwell JE; Brull SJ; Soto RG
    Anesthesiology; 2008 Nov; 109(5):816-24. PubMed ID: 18946293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Lee C; Katz RL
    J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.
    Gijsenbergh F; Ramael S; Houwing N; van Iersel T
    Anesthesiology; 2005 Oct; 103(4):695-703. PubMed ID: 16192761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation.
    de Boer HD; van Egmond J; van de Pol F; Bom A; Driessen JJ; Booij LH
    Br J Anaesth; 2006 Nov; 97(5):681-6. PubMed ID: 17018564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    Brueckmann B; Sasaki N; Grobara P; Li MK; Woo T; de Bie J; Maktabi M; Lee J; Kwo J; Pino R; Sabouri AS; McGovern F; Staehr-Rye AK; Eikermann M
    Br J Anaesth; 2015 Nov; 115(5):743-51. PubMed ID: 25935840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sugammadex: A Review of Neuromuscular Blockade Reversal.
    Keating GM
    Drugs; 2016 Jul; 76(10):1041-52. PubMed ID: 27324403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new approach to anesthesia management in myasthenia gravis: reversal of neuromuscular blockade by sugammadex.
    de Boer HD; van Egmond J; Driessen JJ; Booij LH
    Rev Esp Anestesiol Reanim; 2010 Mar; 57(3):181-4. PubMed ID: 20422852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial.
    Czarnetzki C; Tassonyi E; Lysakowski C; Elia N; Tramèr MR
    Anesthesiology; 2014 Jul; 121(1):59-67. PubMed ID: 24608361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.